Fabian Hauck

Fabian Hauck

Auto-generated profile, based on publicly available information

Fabian Hauck

Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universitat, Munich, Germany; University Children's Hospital Heidelberg-Mannheim Ltd., Ruprecht-Karls-Universitat Heidelberg, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
CSCharlotte Schwab
Charlotte Schwab
AGAnnemarie Gabrysch
Annemarie Gabrysch
POPeter Olbrich
Peter Olbrich
VPVirginia Patiño
Virginia Patiño
KWKlaus Warnatz
Klaus Warnatz
BGBodo Grimbacher
Bodo Grimbacher

3 February 2011 in Blood
Verified
Journal Article
Open access
PDF file
JSJana Pachlopnik Schmid
Jana Pachlopnik Schmid
DCDanielle Canioni
Danielle Canioni
DMDespina Moshous
Despina Moshous
FTFabien Touzot
Fabien Touzot
NMNizar Mahlaoui
Nizar Mahlaoui
SLSylvain Latour
Sylvain Latour
X-linked lymphoproliferative syndromes (XLP) are primary immunodeficiencies characterized by a particular vulnerability toward Epstein-Barr virus infection, frequently resulting in hemophagocytic lymphohistiocytosis (HLH). XLP type 1 (XLP-1) is caused by mutations in the gene SH2D1A (also named SAP), whereas mutations in the gene XIAP underlie XLP type 2 (XLP-2). Here, a comparison of the clinical phenotypes associated with XLP-1 and XLP-2 was performed in cohorts of 33 and 30 patients, respectively. HLH (XLP-1, 55%; XLP-2, 76%) and hypogammaglobulinemia (XLP-1, 67%; XLP-2, 33%) occurred in both groups. Epstein-Barr virus infection in XLP-1 and XLP-2 was the common trigger of HLH (XLP-1, 92%; XLP-2, 83%). Survival rates and mean ages at the first HLH episode did not differ for both groups, but HLH was more severe with lethal outcome in XLP-1 (XLP-1, 61%; XLP-2, 23%). Although only XLP-1 patients developed lymphomas (30%), XLP-2 patients (17%) had chronic hemorrhagic colitis as documented by histopathology. Recurrent splenomegaly often associated with cytopenia and fever was preferentially observed in XLP-2 (XLP-1, 7%; XLP-2, 87%) and probably represents minimal forms of HLH as documented by histopathology. This first phenotypic comparison of XLP subtypes should help to improve the diagnosis and the care of patients with XLP conditions.

28 May 2014 in Nature
Verified
Journal Article
Closed access
PDF file
EMEmmanuel Martin
Emmanuel Martin
NPNoé Palmic
Noé Palmic
SSSylvia Sanquer
Sylvia Sanquer
CLChristelle Lenoir
Christelle Lenoir
FHFabian Hauck
Fabian Hauck
SLSylvain Latour
Sylvain Latour

11 June 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DBDavid Boutboul
David Boutboul
HKHye Sun Kuehn
Hye Sun Kuehn
ZWZoé Van de Wyngaert
Zoé Van de Wyngaert
JNJulie E. Niemela
Julie E. Niemela
ICIsabelle Callebaut
Isabelle Callebaut
SRSergio D. Rosenzweig
Sergio D. Rosenzweig
Ikaros/IKZF1 is an essential transcription factor expressed throughout hematopoiesis. IKZF1 is implicated in lymphocyte and myeloid differentiation and negative regulation of cell proliferation. In humans, somatic mutations in IKZF1 have been linked to the development of B cell acute lymphoblastic leukemia (ALL) in children and adults. Recently, heterozygous germline IKZF1 mutations have been identified in patients with a B cell immune deficiency mimicking common variable immunodeficiency. These mutations demonstrated incomplete penetrance and led to haploinsufficiency. Herein, we report 7 unrelated patients with a novel early-onset combined immunodeficiency associated with de novo germline IKZF1 heterozygous mutations affecting amino acid N159 located in the DNA-binding domain of IKZF1. Different bacterial and viral infections were diagnosed, but Pneumocystis jirovecii pneumonia was reported in all patients. One patient developed a T cell ALL. This immunodeficiency was characterized by innate and adaptive immune defects, including low numbers of B cells, neutrophils, eosinophils, and myeloid dendritic cells, as well as T cell and monocyte dysfunctions. Notably, most T cells exhibited a naive phenotype and were unable to evolve into effector memory cells. Functional studies indicated these mutations act as dominant negative. This defect expands the clinical spectrum of human IKZF1-associated diseases from somatic to germline, from haploinsufficient to dominant negative.

7 December 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RLRomain Lévy
Romain Lévy
SOSatoshi Okada
Satoshi Okada
Vivien BéziatVivien Béziat
Vivien Béziat
KMKunihiko Moriya
Kunihiko Moriya
CLCaini Liu
Caini Liu
APAnne Puel
Anne Puel
Significance: Chronic mucocutaneous candidiasis (CMC) is defined as persistent or recurrent infections of the skin and/or mucosae by commensal fungi of the Candida genus. It is often seen in patients with T-cell deficiencies, whether inherited or acquired, who typically suffer from multiple infectious diseases. Rare patients are otherwise healthy and display isolated CMC, which often segregates as a Mendelian trait. In 2011, we described the first genetic cause of isolated CMC, with autosomal recessive (AR), complete IL-17 receptor A (IL-17RA) deficiency, in a single patient. We report here 21 patients from 12 unrelated kindreds, homozygous for 12 different mutant alleles that underlie AR IL-17RA deficiency. All patients have isolated CMC and their cells do not respond to IL-17A, -17F, and -17E/IL-25.

3 September 2020 in Blood
Verified
Journal Article
Closed access
RCRobert Chiesa
Robert Chiesa
JWJunfeng Wang
Junfeng Wang
HBHenric-Jan Blok
Henric-Jan Blok
SHSheree Hazelaar
Sheree Hazelaar
BNBenedicte Neven
Benedicte Neven
MSMary A. Slatter
Mary A. Slatter
Chronic granulomatous disease (CGD) is a primary immunodeficiency resulting in life-threatening infections and inflammatory complications. Allogeneic hematopoietic cell transplantation (allo-HCT) can cure the disease, but the indication to transplant remains controversial. We performed a retrospective multicenter study of 712 patients with CGD who underwent allo-HCT transplantation from March 1993 through December 2018. We studied 635 children (aged 1 antigen mismatch. Choice of conditioning regimen did not influence OS or EFS. In summary, we report an excellent outcome after allo-HCT in CGD, with low incidence of graft failure and mortality in all ages. Older patients and recipients of 1-antigen-mismatched grafts had a less favorable outcome. Transplantation should be strongly considered at a younger age and particularly in the presence of a well-matched donor.